Sacramento & San Diego, California, August 4, 2026
Lunai Bioworks Inc. has announced a definitive Master Collaboration Agreement with BrainStorm Therapeutics to accelerate the development of precision therapies for Parkinson’s disease by combining artificial intelligence, patient-derived human brain organoids, biomarker discovery, and translational validation. The collaboration integrates Lunai’s wholly owned subsidiary BioSymetrics’ Contingent AI™ patient-stratification platform with BrainStorm’s advanced human midbrain organoid technology to create a comprehensive drug discovery workflow capable of identifying disease mechanisms, validating therapeutic targets, and supporting future pharmaceutical partnerships. Alongside the collaboration, BioSymetrics released a new technical white paper outlining AI-driven phenoclustering strategies for Parkinson’s disease, while the companies confirmed that the first collaborative data readout is expected during the first half of 2027. The partnership represents an important step toward improving precision neuroscience by transforming computational discoveries into biologically validated therapeutic opportunities for one of the world’s fastest-growing neurodegenerative diseases.
AI and Human Brain Organoids Create Precision Neuroscience Platform
The collaboration establishes a unique end-to-end precision medicine workflow that combines AI-powered patient stratification with human translational validation. BioSymetrics’ proprietary Contingent AI™ platform analyzed data from the internationally recognized Parkinson’s Progression Markers Initiative (PPMI) to identify clinically distinct Parkinson’s disease subtypes associated with rapid motor decline, cognitive deterioration, and unique biological signatures. These computational findings will now be experimentally validated using BrainStorm Therapeutics’ patient-derived familial Parkinson’s disease midbrain organoid platform, which integrates human genetics, single-cell transcriptomics, functional phenotyping, and artificial intelligence. Together, the technologies are designed to identify biologically meaningful disease mechanisms, discover novel biomarkers, prioritize therapeutic targets, and establish stronger scientific evidence before drug candidates advance into clinical development. By connecting computational analysis with human laboratory models, the companies aim to overcome one of the greatest challenges in precision neurology—linking patient heterogeneity to actionable therapeutic biology.
Three-Stage Strategy Supports Drug Development and Biomarker Discovery
The agreement outlines a three-stage commercial strategy designed to generate value across multiple phases of pharmaceutical development. In the near term, Lunai’s AI platform will help pharmaceutical companies improve clinical trial design, patient selection, and endpoint optimization by identifying more precisely defined patient populations. During the medium term, the collaboration will refine subtype-associated proteomic signatures into deployable biomarker panels that may eventually support patient stratification, treatment-response monitoring, and future companion diagnostic development following appropriate validation. Over the longer term, BrainStorm’s patient-derived human midbrain organoids will serve as highly relevant experimental systems for validating AI-prioritized therapeutic targets and subtype-specific disease mechanisms. The integrated workflow is expected to generate partner-ready therapeutic programs supported by validated biomarkers, human translational evidence, and clearly defined patient populations, creating new opportunities for licensing, co-development, and pharmaceutical partnerships.
Advertisement
Collaboration Advances Next-Generation Parkinson’s Research
The partnership strengthens Lunai Bioworks’ growing position in AI-driven precision medicine while reinforcing BrainStorm Therapeutics’ leadership in human organoid-based neuroscience research. Parkinson’s disease remains highly heterogeneous, making patient selection and target identification major challenges for successful drug development. By combining computational biology with advanced laboratory validation, the companies seek to improve the efficiency of discovering disease-modifying therapies capable of addressing specific biological subtypes rather than treating Parkinson’s disease as a single condition. The collaboration also reflects increasing industry interest in integrating artificial intelligence, biomarker discovery, human organoid technologies, and precision medicine to improve clinical success rates. With an initial collaborative data readout targeted for the first half of 2027, the alliance positions both organizations to support future pharmaceutical partnerships while accelerating the development of innovative therapies for patients living with Parkinson’s disease.
Source: Lunai Bioworks press release
